(Q46570218)

23 December 2017

title

5-Azacitidine has limited therapeutic activity in myelofibrosis (English)

1 reference

23 December 2017

8

A Tefferi

1 reference

23 December 2017

R A Mesa

1

1 reference

23 December 2017

S Verstovsek

2

1 reference

23 December 2017

C Rivera

3

1 reference

23 December 2017

A Pardanani

4

1 reference

23 December 2017

K Hussein

5

1 reference

23 December 2017

T Lasho

6

1 reference

23 December 2017

W Wu

7

1 reference

23 December 2017

publication date

29 May 2008

1 reference

23 December 2017

published in

Leukemia

1 reference

23 December 2017

volume

23

1 reference

23 December 2017

issue

1

1 reference

23 December 2017

page(s)

180-182

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1038/leu.2008.136

exact match

0 references

cites work

New and old treatment modalities in primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

Bortezomib therapy in myelofibrosis: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.136

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.136

1 reference

23 December 2017

1 reference

23 December 2017